Latest news
Whitehawk Therapeutics 2Q Research and Development Expenses $12.9M >WHWK - MoomooMoomoo · Fri, 07 Aug 2026 03:38:41 GMTWhitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:11:01 GMTWHWK: Net loss of $38.8M in H1 2026; $190M cash; advancing ADC pipeline after FYARRO divestiture - TradingViewTradingView · Thu, 06 Aug 2026 20:05:47 GMTWhitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingViewTradingView · Thu, 06 Aug 2026 14:13:02 GMTWHWK: Q2 2026 net loss narrowed to $16.6M, cash runway extended to 2H 2028, and pipeline advanced - TradingViewTradingView · Thu, 06 Aug 2026 14:11:49 GMTWhitehawk Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:06:55 GMTWhitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR NewswirePR Newswire · Thu, 06 Aug 2026 12:00:00 GMTWhitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and Resistance - Wave Extension - dars.gov.etdars.gov.et · Thu, 06 Aug 2026 02:33:12 GMT